sellWeak10b5-1 plan
Volkow Ben sold $9,110 of ULY
director at Urgent.ly Inc.. 2,256 shares at an average of $4.04, traded Jun 18, 2025, filed Jun 20, 2025.
Warning score
0Value
$9,110
2,256 shares
Holdings after
19,257
-10% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- 0Trade size$9k at market
- +5Share of holdings soldSold 10% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-088561, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 18, 2025 | SOpen-market sale Common Stock10b5-1 | -2,256 | $4.04 | $9,110 | 19,257 | Jun 20, 2025 |
Related signals
Other insiders at Urgent.ly Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Urgent.ly Inc. | Volkow Ben director | $8,934 2,257 shares | -16% | |
| 0Weak | Urgent.ly Inc. | Volkow Ben director | $6,197 1,356 shares | -9% | |
| 0Weak | Urgent.ly Inc. | Volkow Ben director | $4,348 900 shares | -5% | |
| 0Weak | Urgent.ly Inc. | Volkow Ben director | $15k 2,256 shares | -12% | |
| 0Weak | Urgent.ly Inc. | Volkow Ben director | $16k 2,256 shares | -9% | |
| 0Weak | Urgent.ly Inc. | Volkow Ben director | $5,965 1,256 shares | -5% | |
| 0Weak | Urgent.ly Inc. | Volkow Ben director | $4,632 1,000 shares | -4% | |
| 0Weak | Urgent.ly Inc. | Volkow Ben director | $7,528 2,256 shares | -8% | |
| 0Weak | Urgent.ly Inc. | Volkow Ben director | $963 2,178 shares | -1% | |
| 0Weak | Urgent.ly Inc. | Volkow Ben director | $4,878 11,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.